Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.
What’s Really Banging Up Biovail? The Canadian drugmaker says a truck accident caused it to lower guidance. Wall Street skeptics think something more may be going on
European biotech – surviving the storm To endure a storm, a sailor must frequently tack and adjust the rigging and the analogy holds true for those at the helm of Europe�s biotechnology companies.
Pharma marketing’s changing skills set As the pharmaceutical industry reacts to change there is a race to find high-calibre commercial executives, but what skills should these individuals possess?
Create Competition In Expanding Biotech Field The biotech field is booming and managed care is scrambling to level the playing field by creating competition.
Bacteria Make More Electricity Researchers from the University of Massachusetts at Amherst have identified a microorganism that is particularly good at converting sugars to electricity under natural conditions.
Geneticists hunt control patterns The Human Epigenome Project will look for patterns in our ‘life code’ that are associated with gene regulation but are also implicated in causing disease. Researchers at Epigenomics AG in Berlin and the Sanger Institute in Cambridge will take part in the five-year study.
Faster Entry Sought for Generics Despite efforts to speed up approval of generic drugs, Americans still spend billions extra for prescriptions because of delays engineered by brand-name pharmaceutical companies. Pending legislation could help.
Biotech IPO Pipeline Fills Up With the biotech sector surging this year, private companies in the field see a chance to pull in some cash. But follow some key steps before buying.
Financing On Target For A Stellar Year It’s beginning to look a lot like 2001 – or better. In the first nine months of 2003, biotech companies raised nearly $11.8 billion in new funds (excluding revenues and payments from corporate partners), putting the sector on track for at least equaling – if not topping -the […]